Lyka Labs Limited

₹80.10As of Sun 8 Nov 2026, 12:00 UTC
NSE:LYKALABSHealthcare
Country India
PE (Fwd) •••
TSR 10Y CAGR 1.66%
Div yield —
ROE (10.74%)
Biotechnology
Beta (5Y) 0.81
PE TTM —
TSR TTM (14.82%)
Mkt cap ₹2.896B
ROIC (7.95%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹82
1.88%
383.86%
Sell 0|9|2|12|11
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
1.57
1.66
1.85
1.93
6.47%
12.54%
26.52%
27.71%
Revenue₹M
140.5
141.0
144.0
147.0
0.41%
(4.15%)
(3.40%)
1.64%
Peers (US$30.27M)
Cap (US$)
PE
117.9M
19.70x
45.23M
26.89x
30.17M
—
Capital
TTM
5Y
10Y
Leveragex
0.702
0.211
0.188
EBIT/Intx
0.773
0.429
0.416
Own earn%
(29.22)
(43.89)
(47.63)
Sh yield%
46.76
17.39
18.43
Owners
Insiders/Inst%
13.35
62.39
Short interest%
2.59
SBC / revenue%
1.37
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
2–10
$1 testx
0.0
Incr. ROIC%
3